Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.
作者信息
Li Wenqing, Shenkar Robert, Detter Mathew R, Moore Thomas, Benavides Christian, Lightle Rhonda, Girard Romuald, Hobson Nicholas, Cao Ying, Li Yan, Griffin Erin, Gallione Carol, Zabramski Joseph M, Ginsberg Mark H, Marchuk Douglas A, Awad Issam A
出版信息
J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI154909.
Abstract
摘要
相似文献
1
Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.在动物模型中，普萘洛尔通过拮抗β1肾上腺素能受体来抑制海绵状血管畸形。
J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI154909.
2
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage.普萘洛尔治疗有症状性出血的海绵状血管畸形
World Neurosurg. 2016 Apr;88:631-639. doi: 10.1016/j.wneu.2015.11.003. Epub 2015 Nov 11.
3
Expression of β1 adrenergic receptor in vascular anomalies in children.β1 肾上腺素能受体在儿童血管畸形中的表达。
J Int Med Res. 2021 Sep;49(9):3000605211047713. doi: 10.1177/03000605211047713.
4
Could propranolol be beneficial in adult cerebral cavernous malformations?普萘洛尔对成人脑海绵状血管畸形有益吗？
Neurosurg Rev. 2019 Jun;42(2):403-408. doi: 10.1007/s10143-018-01074-0. Epub 2019 Jan 4.
5
Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.普萘洛尔治疗家族性脑静脉畸形（Treat_CCM）：一项随机对照先导试验的研究方案。
Trials. 2020 May 12;21(1):401. doi: 10.1186/s13063-020-4202-x.
6
Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study.普萘洛尔可减少脑海绵状血管畸形病变的发展并挽救其屏障功能：一项临床前研究。
Stroke. 2021 Apr;52(4):1418-1427. doi: 10.1161/STROKEAHA.120.029676. Epub 2021 Feb 23.
7
Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism.β(2)-肾上腺素能受体拮抗作用对脉络膜新生血管的抑制。
JAMA Ophthalmol. 2013 Mar;131(3):376-82. doi: 10.1001/jamaophthalmol.2013.1476.
8
β- and β/β-adrenergic receptor antagonists block 6-nitrodopamine-induced contractions of the rat isolated epididymal vas deferens.β-和β/β-肾上腺素能受体拮抗剂可阻断 6-硝基多巴胺引起的大鼠离体附睾输精管收缩。
Naunyn Schmiedebergs Arch Pharmacol. 2022 Oct;395(10):1257-1268. doi: 10.1007/s00210-022-02268-6. Epub 2022 Jul 8.
9
Letter by Filippidis et al regarding article, "Evaluating strategies for the treatment of cerebral cavernous malformations".菲利皮迪斯等人就“评估脑海绵状血管畸形的治疗策略”一文所写的信。
Stroke. 2011 May;42(5):e373. doi: 10.1161/STROKEAHA.110.606251. Epub 2011 Mar 10.
10
Inhibition of a TREK-like K+ channel current by noradrenaline requires both β1- and β2-adrenoceptors in rat atrial myocytes.去甲肾上腺素对类TREK钾通道电流的抑制作用在大鼠心房肌细胞中需要β1和β2肾上腺素能受体同时参与。
Cardiovasc Res. 2014 Oct 1;104(1):206-15. doi: 10.1093/cvr/cvu192. Epub 2014 Sep 9.
引用本文的文献
1
Focused ultrasound augments the delivery and penetration of model therapeutics into cerebral cavernous malformations.聚焦超声增强了模型治疗药物向脑海绵状血管畸形的递送和渗透。
J Control Release. 2025 Jul 10;383:113861. doi: 10.1016/j.jconrel.2025.113861. Epub 2025 May 16.
2
Genetic inactivation of the β1 adrenergic receptor prevents cerebral cavernous malformations in zebrafish.β1肾上腺素能受体的基因失活可预防斑马鱼脑海绵状血管畸形。
Elife. 2025 Feb 24;13:RP99455. doi: 10.7554/eLife.99455.
3
Focused Ultrasound Augments the Delivery and Penetration of Model Therapeutics into Cerebral Cavernous Malformations.聚焦超声增强模型治疗药物向脑海绵状血管畸形的递送与穿透。
bioRxiv. 2025 Jan 23:2024.08.27.609060. doi: 10.1101/2024.08.27.609060.
4
Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations.除了对强抗值外，雷帕霉素会增加小鼠脑海绵状血管畸形模型中的病灶负担。
Transl Stroke Res. 2025 Jun;16(3):859-867. doi: 10.1007/s12975-024-01270-9. Epub 2024 Jul 9.
5
Bringing CCM into a dish: cell culture models for cerebral cavernous malformations.将大脑海绵状血管畸形研究引入培养皿：大脑海绵状血管畸形的细胞培养模型
Med Genet. 2021 Dec 3;33(3):251-259. doi: 10.1515/medgen-2021-2091. eCollection 2021 Sep.
6
Genetic Inactivation of the β1 adrenergic receptor prevents Cerebral Cavernous Malformations in zebrafish.β1肾上腺素能受体的基因失活可预防斑马鱼的脑海绵状畸形。
bioRxiv. 2024 Nov 22:2024.05.05.592554. doi: 10.1101/2024.05.05.592554.
7
Clinical Features and Treatment of Pediatric Cerebral Cavernous Malformations.小儿脑海绵状血管畸形的临床特征与治疗
J Korean Neurosurg Soc. 2024 May;67(3):299-307. doi: 10.3340/jkns.2024.0047. Epub 2024 Mar 28.
8
Patient-reported outcome measures in patients with familial cerebral cavernous malformations: results from the Treat_CCM trial.家族性脑海绵状血管畸形患者的患者报告结局指标：Treat_CCM试验结果
Front Neurol. 2024 Feb 14;15:1338941. doi: 10.3389/fneur.2024.1338941. eCollection 2024.
9
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.有症状性出血的海绵状血管畸形的试验准备，第二部分：生物标志物和试验模型。
Stroke. 2024 Jan;55(1):31-39. doi: 10.1161/STROKEAHA.123.044083. Epub 2023 Dec 22.
10
Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view.β受体阻滞剂在心律失常中的应用——临床药理学家的观点
Front Pharmacol. 2023 Jan 9;13:1043714. doi: 10.3389/fphar.2022.1043714. eCollection 2022.
Zotero 插件